These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 38855861)
1. Short-term changes in serum miRNA levels and patient-reported clinical outcomes in myasthenia gravis. Huang YF; Bhandage AK; Adeström LD; Punga AR Muscle Nerve; 2024 Aug; 70(2):284-289. PubMed ID: 38855861 [TBL] [Abstract][Full Text] [Related]
2. Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis. Sabre L; Maddison P; Sadalage G; Ambrose PA; Punga AR J Neuroimmunol; 2018 Aug; 321():164-170. PubMed ID: 29804819 [TBL] [Abstract][Full Text] [Related]
3. miR-30e-5p as predictor of generalization in ocular myasthenia gravis. Sabre L; Maddison P; Wong SH; Sadalage G; Ambrose PA; Plant GT; Punga AR Ann Clin Transl Neurol; 2019 Feb; 6(2):243-251. PubMed ID: 30847357 [TBL] [Abstract][Full Text] [Related]
4. Towards Personalized Medicine in Myasthenia Gravis: Role of Circulating microRNAs miR-30e-5p, miR-150-5p and miR-21-5p. Beretta F; Huang YF; Punga AR Cells; 2022 Feb; 11(4):. PubMed ID: 35203389 [TBL] [Abstract][Full Text] [Related]
5. Circulating miRNAs as Potential Biomarkers in Myasthenia Gravis: Tools for Personalized Medicine. Sabre L; Punga T; Punga AR Front Immunol; 2020; 11():213. PubMed ID: 32194544 [TBL] [Abstract][Full Text] [Related]
6. Estrogen Receptor, Inflammatory, and FOXO Transcription Factors Regulate Expression of Myasthenia Gravis-Associated Circulating microRNAs. Fiorillo AA; Heier CR; Huang YF; Tully CB; Punga T; Punga AR Front Immunol; 2020; 11():151. PubMed ID: 32153563 [TBL] [Abstract][Full Text] [Related]
7. Disease specific signature of circulating miR-150-5p and miR-21-5p in myasthenia gravis patients. Punga AR; Andersson M; Alimohammadi M; Punga T J Neurol Sci; 2015 Sep; 356(1-2):90-6. PubMed ID: 26095457 [TBL] [Abstract][Full Text] [Related]
8. Circulating microRNAs as potential biomarkers in myasthenia gravis patients. Punga AR; Punga T Ann N Y Acad Sci; 2018 Jan; 1412(1):33-40. PubMed ID: 29125182 [TBL] [Abstract][Full Text] [Related]
9. Plasma exosomal miR-106a-5p expression in myasthenia gravis. Xu H; Bao Z; Liang D; Li M; Wei M; Ge X; Liu J; Li J Muscle Nerve; 2020 Mar; 61(3):401-407. PubMed ID: 31889318 [TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Markou A; Sourvinou I; Vorkas PA; Yousef GM; Lianidou E Lung Cancer; 2013 Sep; 81(3):388-396. PubMed ID: 23756108 [TBL] [Abstract][Full Text] [Related]
11. Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients. Zhong H; Lu J; Jing S; Xi J; Yan C; Song J; Luo S; Zhao C J Neuroimmunol; 2020 Nov; 348():577383. PubMed ID: 32961347 [TBL] [Abstract][Full Text] [Related]
12. Gender differences in clinical outcomes in myasthenia gravis: A prospective cohort study. Thomsen JLS; Vinge L; Harbo T; Andersen H Muscle Nerve; 2021 Nov; 64(5):538-544. PubMed ID: 34036597 [TBL] [Abstract][Full Text] [Related]
13. MicroRNA expression profiles of peripheral blood and mononuclear cells in myasthenia gravis: A systematic review. Saghazadeh A; Rezaei N Int Immunopharmacol; 2022 Nov; 112():109205. PubMed ID: 36087508 [TBL] [Abstract][Full Text] [Related]
14. MicroRNA signature associated with treatment response in myasthenia gravis: A further step towards precision medicine. Cavalcante P; Mizrachi T; Barzago C; Scandiffio L; Bortone F; Bonanno S; Frangiamore R; Mantegazza R; Bernasconi P; Brenner T; Vaknin-Dembinsky A; Antozzi C Pharmacol Res; 2019 Oct; 148():104388. PubMed ID: 31401213 [TBL] [Abstract][Full Text] [Related]
15. Increased plasma levels of miR-124-3p, miR-125b-5p and miR-192-5p are associated with outcomes in acute ischaemic stroke patients receiving thrombolysis. He XW; Shi YH; Liu YS; Li GF; Zhao R; Hu Y; Lin CC; Zhuang MT; Su JJ; Liu JR Atherosclerosis; 2019 Oct; 289():36-43. PubMed ID: 31450012 [TBL] [Abstract][Full Text] [Related]
16. Addressing the unsolved challenges in microRNA-based biomarker development: Suitable endogenous reference microRNAs for SARS-CoV-2 infection severity. Belmonte T; Perez-Pons M; Benítez ID; Molinero M; García-Hidalgo MC; Rodríguez-Muñoz C; Gort-Paniello C; Moncusí-Moix A; Madè A; Devaux Y; Martelli F; Ortega A; González J; Torres G; Barbé F; de Gonzalo-Calvo D Int J Biol Macromol; 2024 Jun; 269(Pt 2):131926. PubMed ID: 38688344 [TBL] [Abstract][Full Text] [Related]
17. Circulating miR-155-5p as a Novel Biomarker of Lumbar Degenerative Disc Disease. Divi SN; Markova DZ; Fang T; Guzek R; Kurd MF; Rihn JA; Hilibrand AS; Anderson DG; Vaccaro AR; Schroeder GD; Kepler CK Spine (Phila Pa 1976); 2020 May; 45(9):E499-E507. PubMed ID: 31770330 [TBL] [Abstract][Full Text] [Related]
18. Study of serum exosome miRNA as a biomarker for early onset adult ouclar myastthenia gravis. Mu Y; Huang X; Yang Y; Huang Z; Chen J; Li S; Dong Y; Chen F; Zhang R; Chen J; Feng H; Zhou Q Gene; 2024 Feb; 896():148034. PubMed ID: 38013129 [TBL] [Abstract][Full Text] [Related]
19. Differential Expression of miRNA in the Peripheral Blood Mononuclear Cells in Myasthenia Gravis with Muscle-Specific Receptor Tyrosine Kinase Antibodies. Tan Y; Zhu L; Cui L; Guan Y Crit Rev Eukaryot Gene Expr; 2021; 31(2):1-15. PubMed ID: 34347975 [TBL] [Abstract][Full Text] [Related]
20. Altered expression of miR-125a-5p in thymoma-associated myasthenia gravis and its down-regulation of foxp3 expression in Jurkat cells. Li J; Qiu D; Chen Z; Du W; Liu J; Mo X Immunol Lett; 2016 Apr; 172():47-55. PubMed ID: 26875774 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]